Page last updated: 2024-11-01

o(6)-benzylguanine and Local Neoplasm Recurrence

o(6)-benzylguanine has been researched along with Local Neoplasm Recurrence in 7 studies

O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity

Research Excerpts

ExcerptRelevanceReference
"This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide."9.14Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009)
"This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)."9.14Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009)
"This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide."5.14Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009)
"This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)."5.14Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009)
"Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)."2.69Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (85.71)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Winiczenko, R1
Górnicki, K1
Kaleta, A1
Janaszek-Mańkowska, M1
Khan, ZA1
Singh, C1
Khan, T1
Ganguly, M1
Bradsher, C1
Goodwin, P1
Petty, JT1
Sandau, C1
Bove, DG1
Marsaa, K1
Bekkelund, CS1
Lindholm, MG1
Salazar, J1
Bermúdez, V1
Olivar, LC1
Torres, W1
Palmar, J1
Añez, R1
Ordoñez, MG1
Rivas, JR1
Martínez, MS1
Hernández, JD1
Graterol, M1
Rojas, J1
Mubarak, Z1
Humaira, A1
Gani, BA1
Muchlisin, ZA1
Gremillet, C1
Jakobsson, JG1
Gomila, A1
Shaw, E1
Carratalà, J1
Leibovici, L1
Tebé, C1
Wiegand, I1
Vallejo-Torres, L1
Vigo, JM1
Morris, S1
Stoddart, M1
Grier, S1
Vank, C1
Cuperus, N1
Van den Heuvel, L1
Eliakim-Raz, N1
Vuong, C1
MacGowan, A1
Addy, I1
Pujol, M1
Cobb, A1
Rieger, E1
Bell, J1
Mallik, S1
Zhao, Z1
Szécsényi, Á1
Li, G1
Gascon, J1
Pidko, EA1
Zhang, GR1
Wolker, T1
Sandbeck, DJS1
Munoz, M1
Mayrhofer, KJJ1
Cherevko, S1
Etzold, BJM1
Lukashuk, L1
Yigit, N1
Rameshan, R1
Kolar, E1
Teschner, D1
Hävecker, M1
Knop-Gericke, A1
Schlögl, R1
Föttinger, K1
Rupprechter, G1
Franconieri, F1
Deshayes, S1
de Boysson, H1
Trad, S1
Martin Silva, N1
Terrier, B1
Bienvenu, B1
Galateau-Sallé, F1
Emile, JF1
Johnson, AC1
Aouba, A1
Vogt, TJ1
Gevensleben, H1
Dietrich, J1
Kristiansen, G1
Bootz, F1
Landsberg, J1
Goltz, D1
Dietrich, D1
Idorn, M1
Skadborg, SK1
Kellermann, L1
Halldórsdóttir, HR1
Holmen Olofsson, G1
Met, Ö1
Thor Straten, P1
Johnson, LE1
Brockstedt, D1
Leong, M1
Lauer, P1
Theisen, E1
Sauer, JD1
McNeel, DG1
Morandi, F1
Marimpietri, D1
Horenstein, AL1
Bolzoni, M1
Toscani, D1
Costa, F1
Castella, B1
Faini, AC1
Massaia, M1
Pistoia, V1
Giuliani, N1
Malavasi, F1
Qiu, J1
Peng, S1
Yang, A1
Ma, Y1
Han, L1
Cheng, MA1
Farmer, E1
Hung, CF1
Wu, TC1
Modak, S1
Le Luduec, JB1
Cheung, IY1
Goldman, DA1
Ostrovnaya, I1
Doubrovina, E1
Basu, E1
Kushner, BH1
Kramer, K1
Roberts, SS1
O'Reilly, RJ1
Cheung, NV1
Hsu, KC1
Salgarello, T1
Giudiceandrea, A1
Calandriello, L1
Marangoni, D1
Colotto, A1
Caporossi, A1
Falsini, B1
Lefrançois, P1
Xie, P1
Wang, L2
Tetzlaff, MT1
Moreau, L1
Watters, AK1
Netchiporouk, E1
Provost, N1
Gilbert, M1
Ni, X1
Sasseville, D1
Wheeler, DA1
Duvic, M1
Litvinov, IV1
O'Connor, BJ1
Fryda, NJ1
Ranglack, DH1
Yang, Y2
Yang, J1
Zhang, X2
Grün, AL1
Emmerling, C1
Aumeeruddy-Elalfi, Z1
Ismaël, IS1
Hosenally, M1
Zengin, G1
Mahomoodally, MF1
Dotsenko, A1
Gusakov, A1
Rozhkova, A1
Sinitsyna, O1
Shashkov, I1
Sinitsyn, A1
Hong, CE1
Kim, JU1
Lee, JW1
Lee, SW1
Jo, IH1
Pandiyarajan, S1
Premasudha, P1
Kadirvelu, K1
Wang, B1
Luo, L1
Wang, D1
Ding, R1
Hong, J1
Caviezel, D1
Maissen, S1
Niess, JH1
Kiss, C1
Hruz, P1
Pockes, S1
Wifling, D1
Keller, M1
Buschauer, A1
Elz, S1
Santos, AF1
Ferreira, IP1
Pinheiro, CB1
Santos, VG1
Lopes, MTP1
Teixeira, LR1
Rocha, WR1
Rodrigues, GLS1
Beraldo, H1
Lohar, S1
Dhara, K1
Roy, P1
Sinha Babu, SP1
Chattopadhyay, P1
Sukwong, P1
Sunwoo, IY1
Lee, MJ1
Ra, CH1
Jeong, GT1
Kim, SK2
Huvinen, E1
Eriksson, JG1
Stach-Lempinen, B1
Tiitinen, A1
Koivusalo, SB1
Malhotra, M1
Suresh, S1
Garg, A1
Wei, L1
Jiang, Y2
Zhou, W1
Liu, S1
Liu, Y1
Rausch-Fan, X1
Liu, Z1
Marques, WL1
van der Woude, LN1
Luttik, MAH1
van den Broek, M1
Nijenhuis, JM1
Pronk, JT1
van Maris, AJA1
Mans, R1
Gombert, AK1
Xu, A1
Sun, J1
Li, J1
Chen, W2
Zheng, R1
Han, Z1
Ji, L1
Shen, WQ1
Bao, LP1
Hu, SF1
Gao, XJ1
Xie, YP1
Gao, XF1
Huang, WH1
Lu, X1
Gostin, PF1
Addison, O1
Morrell, AP1
Zhang, Y2
Cook, AJMC1
Liens, A1
Stoica, M1
Ignatyev, K1
Street, SR1
Wu, J1
Chiu, YL1
Davenport, AJ1
Qiu, Z1
Shu, J1
Tang, D1
Gao, X1
Zhang, J3
Huang, K1
Wai, H1
Du, K1
Anesini, J1
Kim, WS1
Eastman, A1
Micalizio, GC1
Liang, JH1
Huo, XK1
Cheng, ZB1
Sun, CP1
Zhao, JC1
Kang, XH1
Zhang, TY1
Chen, ZJ1
Yang, TM1
Wu, YY1
Deng, XP1
Zhang, YX1
Salem, HF1
Kharshoum, RM1
Abou-Taleb, HA1
AbouTaleb, HA1
AbouElhassan, KM1
Ohata, C1
Ohyama, B1
Kuwahara, F1
Katayama, E1
Nakama, T1
Kobayashi, S1
Kashiwagi, T1
Kimura, J1
Lin, JD1
Liou, MJ1
Hsu, HL1
Leong, KK1
Chen, YT1
Wang, YR1
Hung, WS1
Lee, HY1
Tsai, HJ1
Tseng, CP1
Alten, B1
Yesiltepe, M1
Bayraktar, E1
Tas, ST1
Gocmen, AY1
Kursungoz, C1
Martinez, A1
Sara, Y1
Huang, S2
Adams, E1
Van Schepdael, A1
Wang, Q1
Chung, CY1
Yang, W1
Yang, G1
Chough, S1
Chen, Y1
Yin, B1
Bhattacharya, R1
Hu, Y1
Saeui, CT1
Yarema, KJ1
Betenbaugh, MJ1
Zhang, H1
Patik, JC1
Tucker, WJ1
Curtis, BM1
Nelson, MD1
Nasirian, A1
Park, S1
Brothers, RM1
Dohlmann, TL1
Hindsø, M1
Dela, F1
Helge, JW1
Larsen, S1
Gayani, B1
Dilhari, A1
Wijesinghe, GK1
Kumarage, S1
Abayaweera, G1
Samarakoon, SR1
Perera, IC1
Kottegoda, N1
Weerasekera, MM1
Nardi, MV1
Timpel, M1
Ligorio, G1
Zorn Morales, N1
Chiappini, A1
Toccoli, T1
Verucchi, R1
Ceccato, R1
Pasquali, L1
List-Kratochvil, EJW1
Quaranta, A1
Dirè, S1
Heo, K1
Jo, SH1
Shim, J1
Kang, DH1
Kim, JH1
Park, JH1
Akhtar, N1
Saha, A1
Kumar, V1
Pradhan, N1
Panda, S1
Morla, S1
Kumar, S1
Manna, D1
Wang, H1
Xu, E1
Yu, S1
Li, D1
Quan, J1
Xu, L1
Saslow, SA1
Um, W1
Pearce, CI1
Bowden, ME1
Engelhard, MH1
Lukens, WL1
Kim, DS1
Schweiger, MJ1
Kruger, AA1
Adair, LS1
Kuzawa, C1
McDade, T1
Carba, DB1
Borja, JB1
Liang, X2
Song, W1
Wang, K1
Zhang, B1
Peele, ME1
Luo, HR1
Chen, ZY1
Fei, JJ1
Du, ZJ1
Yi, KJ1
Im, WT1
Kim, DW1
Ji, X1
Zhang, C1
Xu, Z1
Ding, Y1
Song, Q1
Li, B2
Zhao, H1
Lee, DW1
Lee, H1
Kwon, BO1
Khim, JS1
Yim, UH1
Park, H1
Park, B1
Choi, IG1
Kim, BS1
Kim, JJ1
Wang, JJ1
Chen, Q1
Li, YZ1
Sakai, M1
Yamaguchi, M1
Nagao, Y1
Kawachi, N1
Kikuchi, M1
Torikai, K1
Kamiya, T1
Takeda, S1
Watanabe, S1
Takahashi, T1
Arakawa, K1
Nakano, T1
Rufo, S1
Continentino, MA1
Nikolaou, V1
Plass, F1
Planchat, A1
Charisiadis, A1
Charalambidis, G1
Angaridis, PA1
Kahnt, A1
Odobel, F1
Coutsolelos, AG1
Fuentes, I1
García-Mendiola, T1
Sato, S1
Pita, M1
Nakamura, H1
Lorenzo, E1
Teixidor, F1
Marques, F1
Viñas, C1
Liu, F1
Qi, P1
Zhang, L1
Quinn, JA4
Jiang, SX3
Reardon, DA3
Desjardins, A3
Vredenburgh, JJ3
Rich, JN3
Gururangan, S3
Friedman, AH3
Bigner, DD3
Sampson, JH3
McLendon, RE4
Herndon, JE4
Walker, A2
Friedman, HS4
Koch, D1
Hundsberger, T1
Boor, S1
Kaina, B1
Weingart, J1
Grossman, SA1
Carson, KA1
Fisher, JD1
Delaney, SM1
Rosenblum, ML1
Olivi, A1
Judy, K1
Tatter, SB1
Dolan, ME2
Pluda, J1
Ewesuedo, RB1
Long, L1
Cokgor, I1
Colvin, OM1
Haglund, MM1
Ashley, DM1
Sampson, J1
Pegg, AE1
Moschel, RC1
Provenzale, JM1
Stewart, ES1
Tourt-Uhlig, S1
Garcia-Turner, AM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474]Phase 10 participants Interventional2001-03-31Completed
Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892]Phase 10 participants Interventional2000-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

6 trials available for o(6)-benzylguanine and Local Neoplasm Recurrence

ArticleYear
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-10, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi

2009
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Neuro-oncology, 2009, Volume: 11, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G

2009
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Cancer, 2009, Jul-01, Volume: 115, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz

2009
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-01, Volume: 25, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2007
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-15, Volume: 18, Issue:20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst

2000

Other Studies

1 other study available for o(6)-benzylguanine and Local Neoplasm Recurrence

ArticleYear
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
    Journal of neuro-oncology, 2007, Volume: 82, Issue:1

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

2007